^
Association details:
| Biomarker: | PSMA1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | JNJ-8177 (Tubulin inhibitor, PSMA-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
41P - Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models
Published date:
10/16/2023
Excerpt:
In vitro studies demonstrate that ARX517 selectively induces cytotoxicity of PSMA-expressing tumor lines….In summary, ARX517 inhibited tumor growth in diverse mCRPC models…
